#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2472	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2923	197.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1671	1671	C	241	C,G,A	230,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4960	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4421	271.8	0	.	n	.	0	T695C	SNP	695	695	T	1453	1453	C	253	C	239	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4960	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4421	271.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	2095	2095	A	346	A,C	335,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4960	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4421	271.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2729	2729	C	390	C,A	374,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4960	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4421	271.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2803	2803	A	372	A	356	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4960	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4421	271.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3355	3355	C	400	C	384	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	826	folP	852	852	100.0	folP.l6.c4.ctg.1	2162	90.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1401	1403	AGC	98;97;98	A;G;C	97;96;97	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1416	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4156	82.6	1	SNP	p	S91F	0	.	.	271	273	TCC	951	953	TCC	61;63;63	T;C;C	57;63;63	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1416	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4156	82.6	1	SNP	p	D95N	0	.	.	283	285	GAC	963	965	GAC	65;65;65	G;A,T;C	65;63,1;65	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1416	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4156	82.6	1	SNP	p	D95G	0	.	.	283	285	GAC	963	965	GAC	65;65;65	G;A,T;C	65;63,1;65	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	155	1416	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4156	82.6	0	HET	.	.	.	C2389A,G,T	.	2389	2389	C	3069	3069	C	97	C,A,G,T	79,10,2,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	578	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1937	72.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	767	769	ACC	145;146;145	A;C;C	136;141;139	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	578	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1937	72.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	782	784	CAC	143;143;144	C,A;A;C	130,1;128;136	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	578	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1937	72.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	965	967	CAC	124;121;118	C;A,C;C,T	121;115,2;113,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	578	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1937	72.8	1	SNP	p	G45D	0	.	.	133	135	GGC	785	787	GGC	144;144;144	G;G;C	132;132;134	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	458	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.2	1683	64.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1592	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3661	105.5	1	SNP	p	D86N	0	.	.	256	258	GAC	977	979	GAC	89;90;90	G;A,G;C	73;59,1;72	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1592	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3661	105.5	1	SNP	p	S87R	0	.	.	259	261	AGT	980	982	AGT	92;93;96	A;G;T,G	62;79;78,3	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1592	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3661	105.5	1	SNP	p	S87W	0	.	.	259	261	AGT	980	982	AGT	92;93;96	A;G;T,G	62;79;78,3	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1592	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3661	105.5	1	SNP	p	S87I	0	.	.	259	261	AGT	980	982	AGT	92;93;96	A;G;T,G	62;79;78,3	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1592	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3661	105.5	1	SNP	p	S88P	0	.	.	262	264	TCC	983	985	TCC	96;96;96	T;C,T;C,T	81;82,4;87,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1778	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3414	126.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1957	1959	GGC	145;145;146	G;G;C	125;124;120	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1619	1621	GCA	125;125;126	G;C,G;A,C	116;115,1;115,4	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1622	1624	ATC	128;128;127	A;T,G,C,A;C	120;120,2,1,1;123	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1634	1636	GTG	126;126;126	G;T,G;G	118;114,1;119	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1634	1636	GTG	126;126;126	G;T,G;G	118;114,1;119	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2138	2140	ACC	73;74;74	A;C;C,G	49;60;65,4	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2192	2194	GCG	64;63;64	G;C,G;G	44;40,1;42	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2192	2194	GCG	64;63;64	G;C,G;G	44;40,1;42	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2315	2317	GGC	66;67;67	G;G,C;C,T,A	66;62,2;60,3,2	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2324	2326	GGC	62;62;62	G;G;C,G	59;48;38,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	948	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2645	84.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2342	2344	CCG	64;63;63	C;C;G,C	58;49;57,2	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1410	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3945	85.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	636	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2655	58.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	1019	1019	C	49	C	38	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	858	860	GGA	100;98;98	G;G;A	99;96;96	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	1119	1121	CTT	59;63;63	C;T,A;T	53;56,1;62	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1143	1145	GGA	72;72;72	G;G;A	67;71;62	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1227	1229	GGT	71;71;72	G;G;T	68;68;69	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1281	1283	AGC	81;81;81	A;G;C	76;77;76	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1347	1347	T	80	T	77	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	1	SNP	p	G120K	0	.	.	358	360	GGT	1074	1076	GGT	56;57;56	G;G;T	52;57;50	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	1	SNP	p	A121N	0	.	.	361	363	GCC	1077	1079	GCC	56;55;55	G;C;C	55;54;54	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	530	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	2367	54.4	1	SNP	p	A121D	0	.	.	361	363	GCC	1077	1079	GCC	56;55;55	G;C;C	55;54;54	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1058	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5530	46.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2347	2349	AAT	69;69;69	A;A;T	68;68;68	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	78	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1298	14.4	1	SNP	p	V57M	1	.	.	169	171	ATG	546	548	ATG	18;18;18	A;T;G	17;17;17	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
